Study Reveals Promising Data on Nilotinib as a Therapy for Diffuse Systemic Sclerosis. Nilotinib was generally well-tolerated by systemic sclerosis patients, with tolerability being primarily limited by mild cardiovascular side effects. Scleroderma News, 08/24/2015. (Also see Clinical trials)
Study Finds Cell Microparticles Correlated with Lung Function in Systemic Sclerosis (SSc) Patients. Investigating microparticles further may help to better understand the pathogenesis of disease and enhance disease activity monitoring in patients with SSc. Scleroderma News, 08/17/2015. (Also see Endothelin and Systemic Scleroderma)
Human Stem Cell Transplantation (HSCT) Revealed As Promising Treatment For Systemic Sclerosis. The HSCT method appears to be a promising treatment of systemic sclerosis disease and the results of this study demonstrate substantial improvement over the course of 12 months treatment. Scleroderma News, 08/20/2015. (Also see Clinical Trials)
Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement (GI) in systemic sclerosis (SSc). Sustained benefit from IVIG suggests a specific immunomodulatory effect on those with established SSc GI complications. PubMed, Rheumatology (Oxford), 08/28/2015. (Also see IVIg and Gastrointestinal Involvement)
Pleural irregularity (PI), a new ultrasound sign for the study of interstitial lung disease(ILD) in systemic sclerosis (SSC) and antisynthetase syndrome (ASS). PI is useful for evaluation of ILD in SSc and ASS patients and can be incorporated into a diagnostic algorithm in SSc patients to reducing the need for exposure to ionising radiation. PubMed, Clin Exp Rheumatol, 08/27/2015. (Also see Pulmonary Fibrosis)
Iloprost Found To Mitigate Raynaud’s Syndrome Symptoms and Heal Associated Digital Ulcers. Iloprost is a safe and effective therapy for secondary Raynaud’s syndrome as it can ease the disease’s symptoms, improve the disability grade and heal or prevent the development of digital ulcers. Scleroderma News, 08/14/2015. (Also see Raynaud's Treatments: Medications and Treatments for Digital Ulcers)
New Potential Serum Biomarker for Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis. The research team concluded that CC16 serum levels can be considered a potential biomarker for ILD in systemic sclerosis patients. Scleroderma News, 08/12/2015. (Also see Pulmonary Fibrosis Diagnosis)
Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab. These data provide further evidence of B-cell involvement in the pathogenesis of scleroderma and targeting B cells may be a promising treatment for scleroderma patients. PubMed, Clin Exp Rheumatol, 2015 Sep-Oct;33 Suppl 91(4):160-167. (Also see B Cells and T Cells and Clinical Trials)
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Pam Hop, Margaret Roof, Winifred Schillberg, Arnold Slotkin, and Juliet Youkhana. Plus donations in honor of Kim Thwaits, and in loving memory of Marta Marx, Jim Miller, and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE sclero.org button.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: